The Federal Reserve's long-awaited rate hike has officially landed, injecting a wave of certainty into global markets. In response, China's A-share market experienced a modest pullback with reduced trading volume, as investors digested the implications of tighter monetary policy.

Despite the overall cautious tone, sector rotation highlighted notable strength in grain-related stocks and innovative drug concepts, which bucked the broader trend to post solid gains. This selective buying suggests that market participants are pivoting toward defensive and policy-driven themes during this adjustment phase.

Turning to specific movers, IMMUNOTECH-B (06978.HK) caught attention as bullish signals emerged on its technical charts. The stock displayed a MACD golden cross formation, a classic indicator often interpreted by traders as a potential upward momentum trigger. With this buy signal flashing, the counter has shown encouraging price action, attracting interest from momentum-focused investors.

Looking ahead, market watchers will keep a close eye on how the Fed's decision influences capital flows into emerging markets, while domestic catalysts such as policy support for food security and healthcare innovation could continue to drive selective outperformance.

As always, investors are advised to monitor volume trends and key technical levels, as the current environment rewards nimble positioning and disciplined risk management.